A Breakthrough in Gene Editing
A new CRISPR therapy is transforming the lives of sickle-cell patients. What could this mean for the technology’s future?
This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here.
I spoke with my colleague Sarah Zhang about a breakthrough in CRISPR therapy, and when it is ethical to use the gene-editing technology.
First, here are three new stories from The Atlantic:
- My father, my faith, and Donald Trump
- Why the Fifth Circuit keeps making such outlandish decisions
- Substack has a Nazi problem.
A Transformative Treatment
Earlier this month, U.K. regulators approved a new therapy that uses CRISPR—a gene-editing technology that allows scientists to make cuts to DNA—to treat people with sickle-cell disease. FDA approval is likely in the coming weeks. I spoke with my colleague Sarah Zhang, who has been covering CRISPR for more than a decade, about this
